文献速递头颈部肿瘤放疗

等待时间对根治性IMRT治疗头颈鳞癌淋巴结分期的影响

Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2016-12-21

这项回顾性研究纳入63例咽部及喉部无淋巴结受累的头颈鳞癌患者,均接受单纯IMRT或联合化疗,按等待时间分析生存、复发及分期升级。结果显示平均等待时间各组无显著差异,14%患者出现分期升级,等待超过50天组有局部失败、淋巴结复发和远处失败,而50天内组无淋巴结或远处失败,分期升级和总生存未受等待时间显著影响。

要点

  • N0头颈鳞癌IMRT等待约50天未显著增加分期升级或复发风险。
  • 等待超过50天组出现19%局部失败、17%淋巴结复发、11%远处失败。
  • 等待50天内组无淋巴结或远处失败,仅1例局部复发。

核心结论

  • 对于接受IMRT的N0头颈鳞癌患者,诊断后等待约50天与分期升级或复发风险过高无显著关联。

研究设计与样本

  • 回顾性研究纳入63例连续咽部及喉部头颈鳞癌患者,均接受单纯IMRT联合或不联合化疗。

主要发现

  • 下咽、喉、口咽亚组平均等待时间分别为62.5天(范围37-102)、63天(范围19-128)、58.5天(范围29-99),组间p=0.725。
  • 9例(14%)患者出现分期升级,18例患者出现局部区域或远处失败。
  • 等待超过50天组中19%患者局部失败、17%淋巴结复发、11%远处失败;等待50天内组无淋巴结或远处失败,仅1例局部复发。
  • 分期升级和总生存未受等待时间增加的显著影响。

临床怎么用

  • 对于N0头颈鳞癌接受根治性IMRT者,诊断后等待约50天未显著增加分期升级或复发风险,可据此评估延迟放疗的安全性。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To evaluate the influence of delays for radiotherapy on survival, recurrence and upstaging for head and neck squamous-cell carcinoma (HNSCC) with no nodal involvement treated with intensity modulated radiotherapy (IMRT). MATERIAL AND METHODS: This retrospective study included 63 consecutive patients with HNSCC located in the pharynx and larynx and treated with exclusive IMRT with or without chemotherapy. Survival, loco-regional or distant failure and upstaging were analyzed according to the waiting time. RESULTS: Mean waiting time for treatment was 62.5 days for the hypopharynx subgroup (range = 37-102), 63 days for the larynx subgroup (range = 19-128) and 58.5 days for the oropharynx subgroup (range = 29-99) (p = 0.725). Nine patients (14%) experienced upstaging. Loco-regional or distant failure occurred in 18 patients. Beyond a delay of 50 days, 19% of patients had local failure, 17% nodal recurrence and 11% distant failure. Within a delay of 50 days, no nodal or distant failure was observed and only 1 patient experienced local recurrence. Upstaging and overall survival were not significantly affected by an increased waiting time. CONCLUSION: For N0 patients treated with IMRT for HNSCC, waiting time around 50 days after the diagnosis was not significantly associated with an excessive risk of upstaging or recurrence.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chevalier C, Bertaut A, Quivrin M, et al. Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy. Clin Transl Radiat Oncol. 2016. PMID: 29657991. doi:10.1016/j.ctro.2016.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。